SABCS: Everolimus No Boon for Refractory HER2-Negative Disease MedPage Today Explain that the addition of everolimus (Afinitor) to paclitaxel (Taxol) for women with HER2-negative breast cancer who do not respond to initial chemotherapy won't improve pathological complete response (pCR). Note that more patients who had ... |
